

What is Claimed Is:

1. A method of expressing an anti-IgE antibody, or a functional variant or fragment thereof, which does not bind to IgE bound to FcεRI, in a host cell comprising introducing an expression vector encoding the anti-IgE antibody, or functional variant or fragment thereof, into a host cell and maintaining the expression in the cell.
2. The method of claim 1, wherein the antibody, or functional variant or fragment thereof, inhibits binding of IgE to FcεRI, FcεRII, or to both receptors.
3. The method of claim 1 or claim 2, wherein the expression vector encodes an anti-IgE antibody Hu-901, having the Accession No. ATCC 11130.
4. The method of claim 1 or claim 2, wherein the nucleic acid encodes an scFv fragment of the anti-IgE antibody Hu-901, having the Accession No. ATCC 11130.
5. A method of inducing a host cell to express an anti-IgE antibody, or a functional variant or fragment thereof, comprising administering an expression vector encoding an anti-IgE antibody, or a functional variant or fragment thereof.
6. The method of claim 5, wherein the antibody, or functional variant or fragment thereof, inhibits binding of IgE to FcεRI, FcεRII, or to both receptors.

7. The method of claim 5 or claim 6, wherein the expression vector encodes an anti-IgE antibody Hu-901, having the Accession No. ATCC 11130.
8. The method of claim 5 or claim 6, wherein the nucleic acid encodes an scFv fragment of anti-IgE antibody Hu-901.
9. A method of expressing in a host cell an anti-IgE antibody, or a functional variant or fragment thereof, comprising administering a formulation comprising a nucleic acid sequence encoding an anti-IgE antibody or a functional variant or fragment thereof, which does not bind to IgE bound to FcεRI.
10. The method of claim 9, wherein the antibody, or functional variant or fragment thereof, inhibits binding of IgE to FcεRI, FcεRII, or to both receptors.
11. The method of claim 9 or claim 10, wherein the nucleic acid encodes an anti-IgE antibody Hu-901, having the Accession No. ATCC 11130.
12. The method of claim 9 or claim 10, wherein the nucleic acid encodes an scFv fragment of the anti-IgE antibody Hu-901, having the Accession No. ATCC 11130.
13. A method of treating an IgE-mediated allergic disease comprising administering a formulation comprising an expression vector encoding an

anti-IgE antibody, or functional variant or fragment thereof, which does not bind to IgE bound to FcεRI.

14. The method of claim 13, wherein the antibody, or functional variant or fragment thereof, inhibits binding of IgE to FcεRI, FcεRII, or to both receptors.
15. The method of claim 13 or claim 14, wherein the expression vector encodes an anti-IgE antibody Hu-901, having the Accession No. ATCC 11130.
16. The method of claim 13 or claim 14, wherein the nucleic acid encodes an scFv fragment of the anti-IgE antibody Hu-901, having the Accession No. ATCC 11130.

0091470-113001